Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12102088 | 1.00 | HRH3 (0.47) | HRH3GRM5GRM1NPC1PARP10 | |
| SCHEMBL3276180 | 1.00 | HRH3 (0.47) | HRH3GRM5GRM1NPC1PARP10 | |
| SCHEMBL3275435 | 0.87 | SPHK2 (0.46) | HRH3SPHK2HCRTR1ALDH1A1 | |
| SCHEMBL12102135 | 0.87 | SPHK2 (0.46) | HRH3SPHK2HCRTR1ALDH1A1 | |
| SCHEMBL3275431 | 0.87 | SPHK2 (0.46) | HRH3SPHK2HCRTR1ALDH1A1 | |
| SCHEMBL3274932 | 0.86 | MET (0.53) | HRH3NPC1PARP10SPHK2ALDH1A1 | |
| SCHEMBL3282430 | 0.86 | MET (0.53) | HRH3NPC1PARP10SPHK2ALDH1A1 | |
| SCHEMBL3274929 | 0.86 | MET (0.53) | HRH3NPC1PARP10SPHK2ALDH1A1 | |
| SCHEMBL12102084 | 0.86 | GRM5 (0.46) | HRH3GRM5GRM1NPC1SPHK2 | |
| SCHEMBL3276455 | 0.86 | GRM5 (0.46) | HRH3GRM5GRM1NPC1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1956952-B | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI | 2013-12-11 | — | — | CN | claimed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | claimed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | claimed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | claimed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | claimed |
| CN-1956952-B | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI | 2013-12-11 | — | — | CN | disclosed |
| EP-1756051-B1 | Histamine H3 receptor agents, preparation and therapeutic uses | LILLY CO ELI (US) | 2012-09-12 | — | — | EP | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696234-B2 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY | 2009-05-07 | — | — | US | disclosed |
| EP-1756051-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005121080-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118254-A1 | (4-Benzyloxy-phenyl)-(2-(S)-pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)- methanone; obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | HRH3, HRH4, HCRTR1 | HRH3 1/4885GRM5 115/4885GRM1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.